Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Examining AstraZeneca’s Farxiga: more than a diabetes drug

At the 2019 ESC congress in Paris, AstraZeneca presented full results from the Phase III DAPA-HF trial studying type 2 diabetes drug Farxiga in HFrEF. The drug showed great promise in this patient group, regardless of whether or not the participants had type 2 diabetes. What are the next steps for Farxiga in the world of CV care?

Download our 2019 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top